Pfizer Inc. (NYSE:PFE) Shares Sold by Oppenheimer & Close LLC

Oppenheimer & Close LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 105,310 shares of the biopharmaceutical company’s stock after selling 7,025 shares during the period. Pfizer accounts for approximately 2.3% of Oppenheimer & Close LLC’s holdings, making the stock its 16th biggest position. Oppenheimer & Close LLC’s holdings in Pfizer were worth $2,794,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Performance

Shares of PFE opened at $26.20 on Friday. The company’s fifty day moving average is $26.17 and its 200-day moving average is $27.04. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm has a market cap of $148.61 billion, a price-to-earnings ratio of 18.58, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.